Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic's (MDT) SenSight claims to deliver patient-specific DBS therapy for the treatment of symptoms associated with Parkinson's, dystonia and essential tremor and medically refractory epilepsy.

Medtronic (MDT) Progresses in Neuromodulation on New FDA Nod

Medtronic plc (NYSE: MDT) has announced clinical trial results from the STROKE atrial fibrillation (AF) trial assessing its Reveal LINQ Insertable Cardiac Monitor (ICM) to detect abnormal heartbeats compared to standard of care. The findings were published in the Journal of the American Medical Association.

Study Shows Medtronic's Cardiac Monitor Tops Standard Care for Atrial Fibrillation Detection

DUBLIN, June 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced clinical trial results from the STROKE AF trial demonstrating the superiority of the Reveal LINQ™ Insertable Cardiac Monitor (ICM) to detect abnormal heartbeats, otherwise known as atrial fibrillation (AF), in both large and small vessel stroke patients compared to standard of care. The findings were published in the June 1, 2021 issue of the Journal of the American Medical Association (JAMA).

Medtronic Insertable Cardiac Monitor Detects Significantly Higher Rates of Atrial Fibrillation in Large and Small Vessel Stroke Patients Compared to Standard of Care

DUBLIN, June 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead System used for Deep Brain Stimulation (DBS) therapy. SenSight is the first-of-its-kind DBS directional lead that combines the benefits of directionality with the power of sensing, allowing physicians to deliver precise, patient-specific DBS therapy for the treatment of some symptoms associated with movement disorders like Parkinson's disease, dystonia and essential tremor, and medically refractory epilepsy.

FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy

Apple

AbbVie

Abbott Labs

Blackrock Inc

Disney

Global X SuperDividend US ETF

Cohen & Steers Closed-End Opportunity Fund

Corning

Home Depot

Xtrackers USD High Yield Corporate Bond ETF

iShares International Select Dividend ETF

JPMorgan Chase & Co

Mastercard

Global X MLP ETF

Altria

Microsoft

NIKE

Realty Income Corp

Global X U.S. Preferred ETF

Prudential Financial

Invesco Nasdaq 100 ETF

iShares Mortgage Real Estate ETF

Starbucks

Schwab US Dividend Equity ETF

The portfolio provided $776 in dividend income during May. However, that amount was 15% lower than a year ago. I added shares to several existing holdings; ABT, DIS, WCLD, VPN, MSFT, AAPL, NKE, and O. I also added QQQM to the portfolio for a growth boost.

My Dividend Growth Portfolio May Update: 35 Holdings And 9 Buys

Medtronic PLC (NYSE: MDT) announced Thursday that it is stopping the distribution and sale of the Medtronic HVAD System, an implantable heart pump, after numerous data indicated higher occurrences of adverse events, including stroke and mortality, as compared to other circulatory-support devices. What Happened: On Thursday morning, the company notified physicians to halt new implants of the HVAD System and shift to an alternative form of mechanical circulatory support.

Medtronic Pulls Plug On Heart Implant Device Amid Growing Concerns Over Patient Safety

Medtronic plc. (MDT) CEO Geoff Martha Presents at Bernstein 37th Annual Strategic Decisions Conference Transcript

Medtronic plc (NYSE: MDT) will stop the distribution and sale of its HVAD System and has notified physicians to cease new implants of the HVAD System and transition to an alternative means of durable mechanical circulatory support. The decision comes after the company's clinical comparisons showed a higher rate of neurological adverse events, including stroke and mortality, with the HVAD System than with other circulatory support devices.

Medtronic Halts Sale of Heart Device HVAD System Over Neurological Adverse Events

DUBLIN, June 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) clearance of patient-specific UNiD™ Rods for use with Medtronic CD Horizon™ Solera™ Voyager™ and Infinity™ OCT spinal systems, expanding the utility of the company's UNiD™ Adaptative Spine Intelligence (ASI) technology. UNiD Rods are designed for each patient and industrially pre-bent prior to surgery to accurately match an artificial intelligence (AI)-driven pre-operative surgical plan, which is created with UNiD™ ASI technology to precisely align patients' spines1 ,2, reducing the risk of malalignment and associated revision surgeries.3 UNiD Rods are used to treat scoliosis, trauma, tumors, and complex degenerative conditions in adults and adolescent idiopathic scoliosis.

Medtronic Gains FDA Clearance of UNiD™ Patient-Specific Rods for Use with CD Horizon™ Solera™ Voyager™ and Infinity™ OCT Spinal Systems

- Company Developing Support Program for Current HVAD Patients - Medtronic Coordinating with Global Regulators to Assure Patient Access to Left Ventricular Assist Devices DUBLIN, June 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, is stopping the distribution and sale of the Medtronic HVAD™ System. This morning, the company notified physicians to cease new implants of the HVAD System and transition to an alternative means of durable mechanical circulatory support.

Medtronic to Stop Distribution and Sale of HVAD™ System

Boston Scientific

Which one of these medical device makers is better poised for a breakout year?

Better Buy: Medtronic or Boston Scientific?

Medtronic plc (MDT) Management Presents at Jefferies Virtual Healthcare Conference (Transcript)

Results Demonstrate 76% Time in Range and 94% Time in Advanced Hybrid Closed Loop Mode DUBLIN, June 2, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 4,120 individuals on the MiniMed™ 780G system, a small subset of those on the latest system today across nine countries in Europe. Data showed an average overall Time in Range of 76.2% and an overnight Time in Range of 83%, mirroring results from the pivotal trial.

Real-World Data on Over 4,000 Patients Using the Medtronic MiniMed™ 780G System Demonstrate Time in Range Mirroring Pivotal Trial

Cardinal Health

Chubb

Clorox

Northrop Grumman

Without growth, your dividend income stream will lose purchasing power to inflation. April was the best dividend investing month of the year.

4 Dividend Increases Expected In June 2021

These two latest innovations are likely to enable Medtronic (MDT) to offer the only pump that adjusts and corrects every five minutes with an infusion set that lasts twice as long.

Medtronic (MDT) Diabetes Arm Secures Two Approvals in Europe

Data on the Company's Holistic Portfolio Will Include Real-World Data on   MiniMed™ 780G System and New Data on Medtronic Continuous Glucose Monitoring Systems and Extended-Wear Infusion Set DUBLIN, June 1, 2021 /PRNewswire/ --  Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced its virtual participation at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place June 2-5, 2021. Medtronic will showcase clinically meaningful outcomes associated with the company's comprehensive product portfolio and future technologies, as well as customer-centric support and services provided in a remote environment during the COVID-19 pandemic, including onboarding and training for healthcare providers and patients.

Medtronic Announces Scientific Data Presentations at the 14th International Conference on Advanced Technologies & Treatments for Diabetes

American Tower

Lowe's

LyondellBasell Industries

Sysco

Universal Corp

This article series covers dividend changes on a weekly basis. A summary table presents relevant data and key statistics of dividend increases.

Dividend Increases: May 22-28, 2021

Titan Medical Inc

Titan Medical Inc (NASDAQ: TMDI) has received $10 million under the second technical milestone under the development and license agreement with Medtronic plc (NYSE: MDT). The development and license agreement provides for developing robotic-assisted surgical technologies for Titan and Medtronic in their respective businesses.

Titan Medical Stock Jumps After Medtronic's $10M Second Milestone Payment

Medtronic plc's (MDT) CEO Geoffrey Martha on Q4 2021 Results - Earnings Call Transcript

Medtronic Plc's (NYSE: MDT) Q4 earnings beat consensus, aided by a recovery in its core business as more people opted for elective procedures that suffered the impact of the COVID-19 pandemic. Q4 adjusted EPS of $1.50 beat the analyst consensus of $1.42, 160% higher than $0.58 from the same period last year.

Medtronic Earnings Double On Procedure Recovery; Hikes Dividend By 9%

The company appeared to turn the corner on COVID-19.

How Medtronic Beat Wall Street Expectations in Its Fiscal Q4

Medtronic's (MDT) fourth-quarter results reflect a strong recovery in terms of elective procedures.

Medtronic's (MDT) Q4 Earnings Beat Estimates, Margins Up

Best Buy

NVIDIA

Pure Storage

Snowflake

Here's a quick look at some earnings reports that were released after markets closed on Wednesday or before Thursday's opening bell.

Earnings Hits and Misses: Best Buy, Medtronic, Nvidia, Pure Storage, Snowflake

Medtronic (MDT) delivered earnings and revenue surprises of 5.63% and 0.55%, respectively, for the quarter ended April 2021. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q4 Earnings and Revenues Beat Estimates

Shares of Medtronic PLC slipped 0.1% in premarket trading Thursday, after the medical technology and services company reported fiscal fourth-quarter profit and sales that rose above expectations, citing a "strong recovery" in elective procedures, and boosted its dividend by 8.6%, but provided a less than upbeat full-year outlook. Net income for the quarter to April 30 rose to $1.36 billion, or $1.00 a share, from $646 million, or 48 cents a share, in the year-ago period.

News for Medtronic Stock (MDT)